Extended Paxlovid fails to ease long COVID symptoms in 959-person trial

Extending Paxlovid to Twenty Five Days Did Not Ease Long COVID Symptoms in a 959 Person Trial

A 959-person NIH trial found that extended Paxlovid did not improve long COVID symptoms versus placebo, testing the lingering virus theory directly.

Longer Paxlovid treatment shows no benefit for long-COVID symptoms, study suggests

The trial found that taking the drug for 25 days was no better than placebo in improving exercise intolerance and cognitive and other symptoms.

Paxlovid did not help long Covid, study finds

Today's health news includes new Trump drug pricing deals, weed edibles and driving research, and Paxlovid for long Covid

Extended Paxlovid fails to ease long COVID symptoms in 959-person trial

Results from a clinical trial and published today in the journal Lancet Infectious Diseases show that the antiviral drug Paxlovid, commonly prescribed to treat acute COVID-19, does not affect long COVID symptoms compared with a placebo.